Steven Nathan
Steven D. Nathan, MBBcH, FCCP, is Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia and is a Professor at the University of Virginia. Dr. Nathan received his medical degree from the University of the Witwatersrand Medical School in Johannesburg, South Africa. Subsequently, he completed a residency in internal medicine at Long Island Jewish Hospital in New York and fellowships in pulmonary medicine, critical care and lung transplantation at Cedars-Sinai Medical Center in Los Angeles. Dr. Nathan has been at Inova Fairfax Hospital since 1996.
Dr. Nathan has authored more than 500 publications, including original research manuscripts, abstracts, reviews, book chapters and three books on idiopathic pulmonary fibrosis. His main areas of research interest include interstitial lung disease, including IPF, pulmonary hypertension, and lung transplantation. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal Thorax. He co-chaired the 6th World Symposium task force for group 3 pulmonary hypertension. He has served on multiple committees, including data safety and monitoring committees and steering committees for clinical trials, where he has also served as chair. He has also served on multiple US Food and Drug Administration advisory boards and is currently the Chair of the FDA Anesthesiology and Respiratory Therapy Devices Panel. Dr. Nathan has delivered talks and served as chairperson of numerous sessions at many national and international conferences.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Boehringer-IngelheimTopic:ILDDate added:07/12/2023Date updated:07/29/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:United TherapeuticsTopic:ILD and PHDate added:07/12/2023Date updated:07/29/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:MerckTopic:COPD and PHDate added:07/12/2023Date updated:07/29/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:DaewoongTopic:IPFDate added:07/12/2023Date updated:07/29/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Trevi TherapeuticsTopic:IPFDate added:07/12/2023Date updated:07/29/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:RoivantTopic:ILD and PHDate added:07/12/2023Date updated:07/29/2024Relationship end date:12/31/2023